Kamada

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Kamada sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Kamada: 4 sponsored US clinical trials, none currently recruiting.

Kamada sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Rabies, with 2 trials.

Upper-quartile sponsor footprint

Kamada sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the Kamada early-phase archive is shaped

4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).

Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Rabies (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Kamada: archived-pipeline peers nationwide

Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Kamada sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Kamada4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab10xBio22nd Century Group23andMe3-C Institute for Social Development
Kamada sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kamada sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Kamada page

4 registered trials is a research-attention snapshot, not an endorsement of Kamada or any single study.

  • None of Kamada's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Rabies is the condition Kamada studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Rabies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kamada pipeline card: 4 registered trials from official public datasets.Report a data error.